HRP20050886B1 - Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol - Google Patents

Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol

Info

Publication number
HRP20050886B1
HRP20050886B1 HR20050886A HRP20050886A HRP20050886B1 HR P20050886 B1 HRP20050886 B1 HR P20050886B1 HR 20050886 A HR20050886 A HR 20050886A HR P20050886 A HRP20050886 A HR P20050886A HR P20050886 B1 HRP20050886 B1 HR P20050886B1
Authority
HR
Croatia
Prior art keywords
alkyl
alkoxycarbonyl
branched
straight
carbon chain
Prior art date
Application number
HR20050886A
Other languages
English (en)
Croatian (hr)
Inventor
Oomura Tomoyuki
Pudipeddi Madhusudhan
Edward Royce Alan
Ruegger Colleen
Sasaki Masaki
Tamura Tokuhiro
Original Assignee
Novartis Ag
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corporation filed Critical Novartis Ag
Publication of HRP20050886A2 publication Critical patent/HRP20050886A2/xx
Publication of HRP20050886B1 publication Critical patent/HRP20050886B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HR20050886A 2003-04-08 2005-10-06 Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol HRP20050886B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr) 2003-04-08 2004-04-06 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number Publication Date
HRP20050886A2 HRP20050886A2 (en) 2006-11-30
HRP20050886B1 true HRP20050886B1 (en) 2011-01-31

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050886A HRP20050886B1 (en) 2003-04-08 2005-10-06 Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Country Status (42)

Country Link
US (11) US20060275357A1 (fr)
EP (5) EP2769713A1 (fr)
JP (3) JP5495467B2 (fr)
KR (3) KR20110005320A (fr)
CN (2) CN101797241B (fr)
AR (3) AR043987A1 (fr)
AT (3) ATE414508T1 (fr)
AU (1) AU2004228929B2 (fr)
BE (2) BE1015972A5 (fr)
BR (1) BRPI0409250B8 (fr)
CA (2) CA2521325C (fr)
CL (2) CL2004000745A1 (fr)
CY (3) CY1110260T1 (fr)
DE (4) DE602004017847D1 (fr)
DK (2) DK1613288T3 (fr)
EC (1) ECSP056090A (fr)
ES (3) ES2228282B1 (fr)
FR (2) FR2854073B1 (fr)
GB (1) GB2400318B (fr)
GR (1) GR1005052B (fr)
HK (3) HK1071685A1 (fr)
HR (3) HRP20050886B1 (fr)
HU (2) HUE028247T2 (fr)
IL (3) IL170888A (fr)
IS (2) IS2682B (fr)
IT (1) ITMI20040682A1 (fr)
LU (1) LU91867I2 (fr)
MA (1) MA27729A1 (fr)
MX (1) MXPA05010860A (fr)
MY (1) MY141249A (fr)
NO (4) NO329332B1 (fr)
NZ (3) NZ592339A (fr)
PE (5) PE20090743A1 (fr)
PL (2) PL1613288T3 (fr)
PT (1) PT1613288E (fr)
RU (5) RU2358716C2 (fr)
SG (1) SG175449A1 (fr)
SI (2) SI2316431T1 (fr)
TN (1) TNSN05256A1 (fr)
TW (1) TWI332847B (fr)
WO (1) WO2004089341A1 (fr)
ZA (1) ZA200507394B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
EP1923055A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
AU2007302296A1 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
EP1905434A1 (fr) * 2006-09-26 2008-04-02 Novartis AG Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
WO2008124210A1 (fr) * 2007-02-14 2008-10-16 Emory University Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
SI2140867T2 (sl) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Farmacevtski sestavek
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
CN101820916A (zh) 2007-10-12 2010-09-01 诺瓦提斯公司 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
JP4846063B2 (ja) 2008-03-17 2011-12-28 アクテリオン ファーマシューティカルズ リミテッド 選択的ｓ１ｐ１レセプターアゴニストの投与法
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CA2735037C (fr) * 2008-09-04 2016-07-12 Cargill Incorporated Compression de l'erythritol
EP2349313A4 (fr) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Thérapie de combinaison avec des peptides époxycétones
JP2012508216A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
KR101463653B1 (ko) 2008-12-17 2014-11-19 다이이찌 산쿄 가부시키가이샤 디아민 유도체의 제조 방법
WO2010082531A1 (fr) 2009-01-13 2010-07-22 第一三共株式会社 Inhibiteur d'un facteur actif de la coagulation sanguine
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN102481296A (zh) * 2009-06-18 2012-05-30 第一三共株式会社 溶解性改善的药用组合物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CN102892417A (zh) 2010-03-01 2013-01-23 欧尼斯治疗公司 用于免疫蛋白酶体抑制的化合物
WO2011115066A1 (fr) 2010-03-19 2011-09-22 第一三共株式会社 Cristal de dérivé de diamine et sa méthode de production
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
CA2797029A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Procede de preparation d'une forme galenique orale comprenant du fingolimod
CA2804262C (fr) 2010-07-02 2016-04-05 Daiichi Sankyo Company, Limited Procede pour la preparation de sel derive de diamine optiquement actif
EP2646409A4 (fr) 2010-11-25 2015-12-16 Shilpa Medicare Ltd Polymorphes du fingolimode et leurs procédés
DK2665471T3 (en) 2011-01-19 2018-03-19 Pathologica Llc ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
CN103732227B (zh) 2011-08-10 2017-04-12 第一三共株式会社 含有二胺衍生物的药物组合物
WO2013091704A1 (fr) 2011-12-22 2013-06-27 Synthon Bv Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US10085955B2 (en) * 2013-01-08 2018-10-02 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (fr) * 2013-03-11 2014-09-18 Astron Research Limited Composition pharmaceutique stable de fingolimod
EP2990055B1 (fr) * 2013-04-26 2019-06-05 Kyoto University Composition comprenant un agoniste du récepteur 1 de la sphingosine-1-phosphate pour empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou pour réduire un tel anévrisme
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (fr) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2974375A1 (fr) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Forme galenique solide stable de fingolimod
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (fr) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Formulations stables de fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2022015348A1 (fr) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Composés sphingoïdes à utiliser dans la prophylaxie et/ou la thérapie d'une infection par un coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (fr) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
EP1050301A1 (fr) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Compositions medicinales
WO2002018395A1 (fr) * 2000-08-31 2002-03-07 Merck & Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DK0778263T3 (da) 1994-08-22 2002-04-22 Mitsubishi Pharma Corp Benzenforbindelser og farmaceutisk anvendelse af disse
EP0812588B1 (fr) 1995-12-28 2004-10-13 Mitsubishi Pharma Corporation Composition pharmaceutique destineé à l'administration topique comprenant de la 2-amino-2-(2-(4-octylphényl)ethyl)propane-1,3-diol pour le traitement des maladies causées par un trouble immunitaire
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (fr) 2001-09-04 2009-03-25 Ono Pharmaceutical Co Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
EP1431284B1 (fr) 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7351725B2 (en) 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
DE602005027074D1 (de) * 2004-07-16 2011-05-05 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (fr) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
EP1050301A1 (fr) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Compositions medicinales
WO2002018395A1 (fr) * 2000-08-31 2002-03-07 Merck & Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs

Also Published As

Publication number Publication date
LU91867I2 (fr) 2011-11-08
DE122011100047I1 (de) 2011-12-15
SI1613288T1 (sl) 2009-04-30
BRPI0409250B8 (pt) 2022-01-18
CA2521325C (fr) 2010-09-14
RU2358716C2 (ru) 2009-06-20
US20140011885A1 (en) 2014-01-09
ATE414508T1 (de) 2008-12-15
EP2008650A2 (fr) 2008-12-31
US20080311188A1 (en) 2008-12-18
DK2316431T3 (en) 2016-01-11
HRP20100601A2 (hr) 2011-03-31
US20200237690A1 (en) 2020-07-30
DE202004021680U1 (de) 2010-04-22
RU2010147000A (ru) 2012-08-10
IS8114A (is) 2005-11-01
NO20055231D0 (no) 2005-11-07
EP2769713A1 (fr) 2014-08-27
DK1613288T3 (da) 2009-03-23
WO2004089341A1 (fr) 2004-10-21
PE20150676A1 (es) 2015-05-17
PE20050396A1 (es) 2005-07-05
GR1005052B (el) 2005-11-30
AR078781A2 (es) 2011-11-30
HRP20050886A2 (en) 2006-11-30
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US8324283B2 (en) 2012-12-04
NO335120B1 (no) 2014-09-22
US20060275357A1 (en) 2006-12-07
CN101797241A (zh) 2010-08-11
RU2475237C2 (ru) 2013-02-20
KR20050121712A (ko) 2005-12-27
RU2012148593A (ru) 2014-05-20
CY1110260T1 (el) 2014-04-09
NO334116B1 (no) 2013-12-16
HRP20100601B1 (hr) 2016-12-02
IL170888A (en) 2010-06-16
FR11C0036I2 (fr) 2023-12-29
RU2009105403A (ru) 2010-08-27
RU2005134173A (ru) 2006-09-10
FR11C0036I1 (fr) 2011-10-14
TWI332847B (en) 2010-11-11
EP1613288B1 (fr) 2008-11-19
DE602004017847D1 (de) 2009-01-02
NO329332B1 (no) 2010-09-27
IE20040246A1 (en) 2004-12-15
MA27729A1 (fr) 2006-01-02
CY2011013I2 (el) 2014-04-09
JP5495467B2 (ja) 2014-05-21
US20110105620A1 (en) 2011-05-05
AT501681A1 (de) 2006-10-15
RU2010146697A (ru) 2012-05-27
AR078782A2 (es) 2011-11-30
ECSP056090A (es) 2006-03-01
ITMI20040682A1 (it) 2004-07-06
IS2682B (is) 2010-10-15
HRP20100600A2 (hr) 2011-03-31
MXPA05010860A (es) 2006-05-25
GB2400318A (en) 2004-10-13
US20190175527A1 (en) 2019-06-13
SI2316431T1 (sl) 2016-04-29
CY1117071T1 (el) 2017-04-05
HUS1100016I1 (hu) 2016-08-29
BRPI0409250B1 (pt) 2017-07-11
JP2004307506A (ja) 2004-11-04
EP2319502A1 (fr) 2011-05-11
KR101367574B1 (ko) 2014-02-25
PE20090743A1 (es) 2009-07-17
EP2316431B1 (fr) 2015-09-30
EP1613288A1 (fr) 2006-01-11
NO2011016I2 (no) 2012-08-27
MY141249A (en) 2010-03-31
PE20131352A1 (es) 2013-11-14
GB0407819D0 (en) 2004-05-12
ZA200507394B (en) 2007-03-28
DE102004016947A1 (de) 2004-10-21
ES2320767T3 (es) 2009-05-28
PT1613288E (pt) 2009-02-25
AT501681B1 (de) 2012-04-15
JP2013177404A (ja) 2013-09-09
NZ586280A (en) 2011-12-22
CY2011013I1 (el) 2014-04-09
IS8885A (is) 2010-02-25
ES2228282A1 (es) 2005-04-01
FR2854073B1 (fr) 2008-03-14
HK1091114A1 (en) 2007-01-12
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
KR20120101148A (ko) 2012-09-12
AU2004228929B2 (en) 2008-02-07
PL1613288T3 (pl) 2009-07-31
CA2521325A1 (fr) 2004-10-21
PE20130200A1 (es) 2013-03-09
US20130108675A1 (en) 2013-05-02
LU91867I9 (fr) 2019-01-03
IL197578A (en) 2015-10-29
US20090203798A1 (en) 2009-08-13
AU2004228929A1 (en) 2004-10-21
NZ542622A (en) 2009-01-31
CN101797241B (zh) 2013-03-27
EP2316431A1 (fr) 2011-05-04
HK1071685A1 (en) 2005-07-29
GB2400318B (en) 2005-08-10
CL2004000745A1 (es) 2005-02-11
IL197578A0 (en) 2011-07-31
BE2011C030I2 (fr) 2023-03-07
TNSN05256A1 (en) 2007-07-10
JP2011006461A (ja) 2011-01-13
GR20040100121A (el) 2004-12-17
ES2228282B1 (es) 2006-02-16
CN1767819A (zh) 2006-05-03
ES2556947T3 (es) 2016-01-21
HUE028247T2 (en) 2016-12-28
CA2707750A1 (fr) 2004-10-21
US20220031609A1 (en) 2022-02-03
AT504853A2 (de) 2008-08-15
HK1155647A1 (en) 2012-05-25
JP5543298B2 (ja) 2014-07-09
IL242037A0 (en) 2015-11-30
EP2008650A3 (fr) 2011-04-27
KR20110005320A (ko) 2011-01-17
BRPI0409250A (pt) 2006-03-28
SG175449A1 (en) 2011-11-28
RU2475236C2 (ru) 2013-02-20
TW200503784A (en) 2005-02-01
NO20100250L (no) 2006-01-09
US20170290787A1 (en) 2017-10-12
AR043987A1 (es) 2005-08-17
NZ592339A (en) 2012-09-28
NO2011016I1 (no) 2011-09-19
NO20131287L (no) 2006-01-09
FR2854073A1 (fr) 2004-10-29
CN1767819B (zh) 2010-07-28
US20140255497A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
HRP20050886B1 (en) Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
EP4344702A3 (fr) Dérivés de pyrazolyle utiles en tant qu&#39;agents anticancéreux
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
KR970707098A (ko) 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
BRPI0407616A (pt) composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste&#34;
ATE517882T1 (de) Chinolinderivate
EP1939175A4 (fr) Dérivé sulfonamide ayant une activité antagoniste de récepteur pgd2
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
AR045551A1 (es) Compuestos fenil o piridil amida como prostaglandina e2 antagonistas
IS8708A (is) Kínasólínafleiður sem æðamyndunarhindranir og milliefni fyrir þær
WO2006017251A3 (fr) Compositions pour l&#39;apport du peptide yy et d&#39;agonistes du pyy
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
BRPI0513888A (pt) composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico
AR041272A1 (es) Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene
HUP0101511A2 (hu) 1-[(1-Szubsztituált-4-piperidinil)-metil]-4-piperidin-származékok, eljárás a vegyületek előállítására, a vegyületeket tartalmazó gyógyászati készítmények és intermedierjeik
TW200626158A (en) Naphthaline derivatives
WO2004104018A3 (fr) Compostions d&#39;administration de peptide yy de d&#39;agonistes pyy
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
SG158925A1 (en) Modulators of chemokine receptor activity, crystalline forms and process
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190401

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200330

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210406

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220404

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20230329

Year of fee payment: 20